The Better Living PA: GLP-1s, Metabolic Health & Midlife Hormones
Oct 16, 2026 · 15 min · 8 segments
Is your GLP-1 dose too high? A higher dose is not automatically better. Semaglutide and tirzepatide work best at the dose that helps you reach your goals while still letting you eat, drink, function…
Okay, first I want to start out and talk a little bit about when GLP-1s first came to market, we were able to treat people for obesity and not just diabetes.
The planned titration schedule, which means this is the instructions that the providers were given who were actually prescribing your medication, often said to start people at the low dose and then move them up every single month until you can get somebody on what we call a targeted maintenance dose.
Now, that being said, when drugs first come out, a lot of times they will have a titration schedule, especially if it's a drug that you're supposed to start off low and move up.
But it became really apparent pretty quickly that not everybody needed to move up once a month.
And now even the current prescribing information for Wegovy and Zepbound says that providers should consider both the treatment response and the tolerability of the dose before they make any changes.
But I definitely saw this in my own practice when people were started off on medications.
GLP-1s at low dose, some people saw great benefits, some people saw absolutely no benefits.
But then as we moved them up, most people would see more side effects as the dose went up.
But it is very evident to me now years into treating people with GLP-1s, that your GLP-1 dose needs to be very personalized to what your body feels the best on.
So at the end of the day, we want you on a dose that's going to help you reach your treatment goals, but still allow you to eat, drink, function, and be happy.
The other thing I want to say up front is that this isn't about judging your treatment by the number on the scale.
Far too many people look at the number on the scale and decide whether or not they think they need to go up or down on their dose.
Okay, first I want to start out and talk a little bit about when GLP-1s first came to market, we were able to treat people for obesity and not just diabetes.
The planned titration schedule, which means this is the instructions that the providers were given who were actually prescribing your medication, often said to start people at the low dose and then move them up every single month until you can get somebody on what we call a targeted maintenance dose.
Now, that being said, when drugs first come out, a lot of times they will have a titration schedule, especially if it's a drug that you're supposed to start off low and move up.
But it became really apparent pretty quickly that not everybody needed to move up once a month.
And now even the current prescribing information for Wegovy and Zepbound says that providers should consider both the treatment response and the tolerability of the dose before they make any changes.
But I definitely saw this in my own practice when people were started off on medications.
GLP-1s at low dose, some people saw great benefits, some people saw absolutely no benefits.
But then as we moved them up, most people would see more side effects as the dose went up.
But it is very evident to me now years into treating people with GLP-1s, that your GLP-1 dose needs to be very personalized to what your body feels the best on.
So at the end of the day, we want you on a dose that's going to help you reach your treatment goals, but still allow you to eat, drink, function, and be happy.
The other thing I want to say up front is that this isn't about judging your treatment by the number on the scale.
Far too many people look at the number on the scale and decide whether or not they think they need to go up or down on their dose.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.